Jim Simons Sensei Biotherapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 215,572 shares of SNSE stock, worth $99,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares

215,572

Previous 223,785 3.67%

Holding current value

$99,163

Previous $138,000 6.52%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.48 - $0.72 $3,942 - $5,913	-8,213 Reduced 3.67%	215,572 $129,000
Q2 2024 Aug 09, 2024	BUY	$0.59 - $1.84 $7,543 - $23,524	12,785 Added 6.06%	223,785 $138,000
Q1 2024 May 13, 2024	BUY	$0.73 - $1.17 $49,269 - $78,965	67,492 Added 47.03%	211,000 $222,000
Q4 2023 Feb 13, 2024	BUY	$0.53 - $0.82 $31,645 - $48,960	59,708 Added 71.25%	143,508 $99,000
Q3 2023 Nov 14, 2023	SELL	$0.75 - $1.32 $4,275 - $7,524	-5,700 Reduced 6.37%	83,800 $67,000
Q2 2023 Aug 11, 2023	SELL	$1.14 - $1.81 $40,698 - $64,617	-35,700 Reduced 28.51%	89,500 $102,000
Q1 2023 May 12, 2023	SELL	$1.31 - $1.7 $62,033 - $80,501	-47,354 Reduced 27.44%	125,200 $188,000
Q4 2022 Feb 13, 2023	SELL	$1.33 - $1.74 $44,217 - $57,848	-33,246 Reduced 16.15%	172,554 $257,000
Q3 2022 Nov 14, 2022	SELL	$1.55 - $2.24 $63,860 - $92,288	-41,200 Reduced 16.68%	205,800 $319,000
Q2 2022 Aug 12, 2022	BUY	$1.49 - $2.3 $244,069 - $376,751	163,805 Added 196.89%	247,000 $561,000
Q1 2022 May 13, 2022	BUY	$2.22 - $6.07 $184,692 - $504,993	83,195 New	83,195 $192,000

Others Institutions Holding SNSE

# of Institutions

Shares Held

2.23M

Call Options Held

Put Options Held

View Full List

About Sensei Biotherapeutics, Inc.

Ticker SNSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,720,300
Market Cap $14.1M
Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...

More about SNSE

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account